Christoph B. Olivier, Annabel Hölzle/LinkedIn
Mar 13, 2026, 22:05
Christoph B. Olivier: Annabel Hölzle Shared Critical Findings on HALT After TAVR
Christoph B. Olivier, Head of the Clinical Trials Unit, UHZ Freiburg, shared on LinkedIn, adding:
”Congratulations Annabel for an outstanding presentation at the Spring School 2026!
Today Annabel Hölzle shared critical findings from her study: ‘Periprocedural hemostatic and inflammatory changes after TAVR and their association with hypoattenuating leaflet thickening (HALT).’
Her research provides vital clues to improve long-term patient safety in heart valve interventions.
We are very proud to see our team members leading such high-impact clinical discussions.
Great job, Annabel!”
Stay updated with Hemostasis Today.
-
Mar 13, 2026, 22:57Robert Hamilton: The Reality of Stroke Care and Why 81.6% Should be a Wake-Up call
-
Mar 13, 2026, 21:29Timothy Glidewell: Genetic Signals of Platelet and Clotting Pathways in Cryptogenic Stroke
-
Mar 13, 2026, 21:19New Canadian Insights on Switching to Longer-Acting Therapy for Hemophilia A – WFH
-
Mar 13, 2026, 21:01Leonardo Roever: Brain Age as a Biomarker of Neuroplasticity and Motor Recovery After Stroke
-
Mar 13, 2026, 20:50William Tembo: Understanding Stroke Through Landmark Clinical Trials
-
Mar 13, 2026, 20:35Jessica Garcia: New Evidence on Thrombin Generation Patterns in Children with Hemophilia A
-
Mar 13, 2026, 20:11Christoph B. Olivier: New Research from Marius Wessinger on Predicting Therapy Success After Pulmonary Embolism
-
Mar 13, 2026, 19:53Wolfgang Miesbach Announces the New English Edition of “Gene Therapy Concepts in the Treatment of Haemophilia”
-
Mar 13, 2026, 17:21Emmanuel J Favaloro: Acquired Hemostasis Disorders Featured in New Issue of Seminars in Thrombosis and Hemostasis